参考文献/References:
[1] Kalantarian S, Stern TA, Mansour M, et al. Cognitive impairment associated with atrial fibrillation: a meta-analysis[J]. Ann Intern Med,2013,158(5 Pt 1):338-346.
[2] Mulder BA, Schnabel RB, Rienstra M. Predicting the future in patients with atrial fibrillation: who develops heart failure?[J]. Eur J Heart Fail,2013,15(4):366-367.
[3] Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives[J]. J Am Coll Cardiol,2014,63(22):2335-2345.
[4] Wijffels MC, Kirchhof CJ, Dorland R,et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats[J]. Circulation,1995,92(7):1954-1968.
[5] Mann SA, Otway R, Guo G, et al. Epistatic effects of potassium channel variation on cardiac repolarization and atrial fibrillation risk[J]. J Am Coll Cardiol,2012,59(11):1017-1025.
[6] Qin M, Huang H, Wang T, et al. Absence of Rgs5 prolongs cardiac repolarization and predisposes to ventricular tachyarrhythmia in mice[J]. J Mol Cell Cardiol,2012,53(6):880-890.
[7] Oh S, Kim KB, Ahn H,et al. Remodeling of ion channel expression in patients with chronic atrial fibrillation and mitral valvular heart disease[J]. Korean J Intern Med,2010,25(4):377-385.
[8] Nattel S, Maguy A, le Bouter S, et al. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation[J]. Physiol Rev,2007,87(2):425-456.
[9] Lu G, Xu S, Peng L,et al. Angiotensin Ⅱ upregulates Kv1.5 expression through ROS-dependent transforming growth factor-beta1 and extracellular signal-regulated kinase 1/2 signalings in neonatal rat atrial myocytes[J]. Biochem Biophys Res Commun,2014,454(3):410-416.
[10] Hu Y, Jones SV, Dillmann WH. Effects of hyperthyroidism on delayed rectifier K+ currents in left and right murine atria[J]. Am J Physiol Heart Circ Physiol,2005,289(4):H1448-H1455.
[11] Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation[J]. Hum Mol Genet,2006,15(14):2185-2191.
[12] Christophersen IE, Olesen MS, Liang B, et al. Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation[J]. Eur Heart J,2013,34(20):1517-1525.
[13] Li GR, Sun HY, Zhang XH, et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+ currents and Na+ current in human atrial myocytes[J]. Cardiovasc Res, 2009,81(2):286-293.
[14] Olsson RI, Jacobson I, Iliefski T, et al. Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel[J]. Bioorg Med Chem Lett,2014,24(5):1269-1273.
[15] Ford JW, Milnes JT. New drugs targeting the cardiac ultra-rapid delayed-rectifier current(I Kur): rationale, pharmacology and evidence for potential therapeutic value[J]. J Cardiovasc Pharmacol,2008,52(2):105-120.
[16] Kiper AK, Rinne S, Rolfes C, et al. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?[J]. Pflugers Arch,2015,467(5):1081-1090.
[17] Yu J, Park MH, Jo SH. Inhibitory effects of cortisone and hydrocortisone on human Kv1.5 channel currents[J].Eur J Pharmacol,2015,746:158-166.
[18] Caballero R, de la Fuente MG, Gomez R, et al. In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both[J]. J Am Coll Cardiol, 2010,55(21):2346-2354.
[19] Ji Q, Liu H, Mei Y,et al. Expression changes of ionic channels in early phase of cultured rat atrial myocytes induced by rapid pacing[J]. J Cardiothorac Surg, 2013,8:194.
[20] Giudicessi JR, Ye D, Tester DJ, et al.Transient outward current(I(to))gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome[J]. Heart Rhythm,2011,8(7):1024-1032.
[21] Torp-Pedersen C, Camm AJ, Butterfield NN,et al. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease[J]. Int J Cardiol,2013,166(1):147-151.
[22] Zhang Z, Zhang C, Wang H, et al.N-3 polyunsaturated fatty acids prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model[J]. Int J Cardiol,2011,153(1):14-20.
[23] Calo L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial[J]. J Am Coll Cardiol,2005,45(10):1723-1728.
[24] European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC)[J]. Europace,2010,12(10):1360-1420.
[25] Iwasaki YK, Nishida K, Kato T,et al. Atrial fibrillation pathophysiology: implications for management[J]. Circulation,2011,124(20):2264-2274.
[26] Voigt N, Li N, Wang Q, et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation[J]. Circulation,2012,125(17):2059-2070.
[27] Liu W, Deng J, Wang G, et al. KCNE2 modulates cardiac L-type Ca(2+)channel[J]. J Mol Cell Cardiol, 2014,72:208-218.
[28] de Ferrari GM, Maier LS, Mont L, et al. Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO(Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion)study[J]. Heart Rhythm,2015,12(5):872-878.
[29] Cavallino C, Facchini M, Veia A, et al.New anti-anginal drugs: ranolazine[J]. Cardiovasc Hematol Agents Med Chem,2015,13(1):14-20.
[30] Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control[J]. Can J Cardiol,2012,28(2):125-136.
[31] Savelieva I, Kakouros N, Kourliouros A,et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part Ⅰ: primary prevention[J]. Europace,2011,13(3):308-328.
[32] Savelieva I, Kakouros N, Kourliouros A,et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part Ⅱ: secondary prevention[J]. Europace,2011,13(5):610-625.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(5):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(5):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]范新荣,等.心房颤动药物治疗的新靶点[J].心血管病学进展,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
FAN Xinrong,ZENG Xiaorong,et al.Novel Targets of Pharmacological Therapies at Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]